IPOL is used for primary and booster vaccination of infants, children and adults to protect against infection with Type 1, Type 2 and Type 3 polioviruses causing poliomyelitis.
Pneumovax® 23 is used for vaccination of children 2 years of age and over and adults to protect against disease caused by 23 types of Streptococcus pneumonia. Pneumovax® 23 is only used in children after the age of 2 years.
Menomune® is used for vaccination of children two years of age and over and adults to protect against four groups of Neisseria meningitidis, group A, group C, group Y and group W-135. Menomune® is only used in children after the age of two years.
Act-HIB™ is used for primary and booster vaccination of infants and children up to their 5th birthday to protect against disease caused by Haemophilus influenzae type b.The vaccine is also used for primary vaccination of children aged 5 years of age and over and adults with some chronic medical conditions. Act-HIB™ is licensed for use in infants and children 2 months to 5 years of age. It is used out of licensure in children 5 years of age and over and adults as there is no alternative vaccine available in New Zealand for these age groups. When children/individuals are older than the age to which the vaccine is licensed, use will be outside of current licensure. No safety concerns are expected for use in older age groups.
ADT™ Booster is used for primary and booster vaccination of children 7 years of age and over and adults to protect against tetanus and diphtheria. An alternative vaccine called Boostrix®, which protects against tetanus, diphtheria and pertussis (whooping cough), can be substituted for one, two or all three doses of the primary vaccinations in these age groups. Both ADT™ Booster and Boostrix® are licensed as booster vaccines. They are used for primary vaccination out of licensure as there is no alternative primary vaccination strength vaccine available in New Zealand for these age groups. When the vaccine is used for a primary vaccination course, use will be outside of current licensure. No safety concerns are expected with use in these circumstances.
Infanrix®-IPV is used for primary and booster vaccination of infants and children to protect against diphtheria, tetanus, pertussis and poliomyelitis. Infanrix®-IPV can also be used for catch-up immunisation for children up to their 10th birthday.
Gardasil® is funded for use for primary immunisation of girls from 9 years of age and young women to protect them from four types of human papillomavirus infection, HIV positive individuals aged 9-26 years, and individuals who are pre- or post-solid organ transplantation. Gardasil® is not funded but can be used for primary immunisation of females who are not eligible for funded vaccine and within the age group of 9 through 45 years and males aged 9 through 26 years to protect them from four types of human papillomavirus infection.
The Institute of Environmental Science & Research Limited (ESR)Sexually transmitted infections in New Zealand 2011 Surveillance Report identified decreasing numbers of new genital warts cases between 2008 and 2011, most notable in 2010 and 2011 and in females aged 15-19 years, corresponding with commencement of the HPV immunisation programme. The Genital Warts pages from the full report are available here. The full ESR report is available from the ESR Public Health Surveillance website.
A short YouTube DVD, The Story of HPV (Human Papillomavirus), provides information for women, parents and caregivers, health workers and students planning to work in the health sector about the human papillomavirus, the Gardasil® vaccine that helps to protect against HPV, and the importance of cervical screening and practising safer sex in protecting women's health.
Synflorix® is used for primary and booster vaccination of infants and children up to their 5th birthday to protect against disease caused by 10 types of streptococcus pneumoniae.
Boostrix® is used for booster vaccination of adolescents aged 11 years and pregnant women between 28-38 weeks gestation* to protect against diphtheria, tetanus and pertussis (whooping cough). Boostrix® can also be used for catch-up immunisation for children aged 7 years# to under 18 years.
*After immunisation protection against pertussis takes up to two weeks to develop. Whilst immunisation between 38-40 weeks gestation is still safe for mother and baby later immunisation means the newborn may still be exposed to the disease by their mother on delivery and/or during the first two weeks of life. The PHARMAC decision to limit funded Boostrix® to 28-38 weeks gestation maximises the benefit of immunisation against pertussis whilst being accountable for the use of public funds. Pregnant women can choose to purchase Boostrix® privately after 38 weeks gestation or at any time after delivery.
#Although Boostrix® is not licensed for use in children aged 7 years to under 10 years it has been used in New Zealand and overseas in this age group and there are no safety concerns with off-label use.
Menactra® is a meningococcal A,C,Y,W-135 conjugate vaccine used to protect against four groups of Neisseria meningitidis, group A, group C, group Y and group W-135.
Menactra® is used as an alternative vaccine to the meningococcal C conjugate vaccines (Meningitec® and Neisvac-C™) and the meningococcal A,C,Y,W-135 polysaccharide vaccines (Menomune® ACYW-135 and Mencevax® ACYW).
The conjugate and polysaccharide vaccines work differently to generate protection against the bacteria. Protection from the conjugate vaccines lasts longer than that from the polysaccharide vaccines. The conjugate vaccines also generate long term memory cells allowing rapid boosting of immunity years later.